Shanghai Pharmaceuticals Holding Co., Ltd
601607
Clasificación en acciones
#2387
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding... Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
Precio por acción
$2.43
Capitalización bursátil
$8.09B
Cambio (1 día)
-1.16%
Cambio (1 año)
-5.94%
País
CN
Comercio Shanghai Pharmaceuticals Holding Co., Ltd (601607)
Categoría
Healthcare
Ratio P/E de Shanghai Pharmaceuticals Holding Co., Ltd (601607)
Ratio P/E al 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Shanghai Pharmaceuticals Holding Co., Ltd, el P/E actual (TTM) de la empresa es 0. Al final de 2026, la empresa tenía un P/E de 0.
Historial del ratio P/E de Shanghai Pharmaceuticals Holding Co., Ltd desde 2001 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2025 | 11.60 | -32.13% |
| 2024 | 17.09 | 4.19% |
| 2023 | 16.40 | 48.37% |
| 2022 | 11.05 | -0.29% |
| 2021 | 11.09 | -8.65% |
| 2020 | 12.14 | -5.13% |
| 2019 | 12.79 | 7.07% |
| 2018 | 11.95 | -35.65% |
| 2017 | 18.57 | 12.84% |
| 2016 | 16.45 | -11.57% |
| 2015 | 18.61 | 8.74% |
| 2014 | 17.11 | -4.75% |
| 2013 | 17.97 | 23.58% |
| 2012 | 14.54 | 10.80% |
| 2011 | 13.12 | -58.75% |
| 2010 | 31.81 | -80.24% |
| 2009 | 160.94 | 221.88% |
| 2008 | 50.00 | -59.78% |
| 2007 | 124.31 | 208.48% |
| 2006 | 40.30 | 28.12% |
| 2005 | 31.45 | 47.65% |
| 2004 | 21.30 | 15.77% |
| 2003 | 18.40 | -31.84% |
| 2002 | 27.00 | 12.69% |
| 2001 | 23.96 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 26.02 | - |
US
|
|
| - | - |
US
|
|
| 34.08 | - |
US
|
|
| - | - |
US
|
|
| 45.62 | - |
AU
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.